<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>BlackWell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25243340</article-id><article-id pub-id-type="pmc">4345959</article-id><article-id pub-id-type="doi">10.1111/bcp.12517</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Trials</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Leaker</surname><given-names>Brian R</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Barnes</surname><given-names>Peter J</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>C Richard</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tutuncu</surname><given-names>Ahmet</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Dave</given-names></name><xref ref-type="aff" rid="au4">4</xref></contrib><aff id="au1"><label>1</label><institution>Respiratory Clinical Trials Ltd</institution><addr-line>London, UK</addr-line></aff><aff id="au2"><label>2</label><institution>National Heart &#x00026; Lung Institute, Imperial College</institution><addr-line>London, UK</addr-line></aff><aff id="au3"><label>3</label><institution>Elevation Pharmaceuticals Inc.</institution><addr-line>San Diego, CA, USA</addr-line></aff><aff id="au4"><label>4</label><institution>Medicines Evaluation Unit, University of Manchester, University Hospital of South Manchester Foundation Trust</institution><addr-line>Manchester, UK</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold>, Dr Brian Leaker MD, Respiratory Clinical Trials Ltd, 20 Queen Anne Street, London W1G&#x02009;8HU, UK., Tel.: 020 7034 3301, Fax: 020 7034 3362, E-mail: <email>brian.leaker@qasmc.com</email></corresp><fn><p>EudraCT number: 2010-018987-17.</p></fn></author-notes><pub-date pub-type="ppub"><month>3</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>20</day><month>2</month><year>2015</year></pub-date><volume>79</volume><issue>3</issue><fpage>492</fpage><lpage>500</lpage><history><date date-type="received"><day>20</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>16</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 John Wiley &#x00026; Sons, Ltd.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><abstract><sec><title>Aims</title><p>To establish the dose&#x02212;response for pharmacodynamics (bronchodilatation), safety and pharmacokinetics for a nebulized formulation of the long acting muscarinic antagonist glycopyrrolate (EP-101) with a high efficiency nebulizer in patients with chronic obstructive pulmonary disease (COPD).</p></sec><sec><title>Methods</title><p>Patients with moderate to severe COPD (GOLD II/III), with reversible lung function, were enrolled into this randomized, double-blind, placebo-controlled, six period crossover study (<italic>n</italic> = 42). Patients received single doses of EP-101 (12.5&#x02013;400&#x02009;&#x003bc;g) and placebo via a high efficiency nebulizer (eFlow&#x000ae; PARI nebulizer), with washout between treatments. Plasma pharmacokinetics were assessed in a subset of patients (<italic>n</italic> = 11).</p></sec><sec><title>Results</title><p>All treatments were well tolerated with similar adverse event rates reported with placebo and at all doses. There were no clinically relevant changes in heart rate, systolic and diastolic blood pressure or in ECG parameters including QT<sub>c</sub> interval. Following treatment with EP-101 at all doses there was a rapid bronchodilator response within 5&#x02009;min. Significant improvements in mean change from baseline FEV<sub>1</sub> at 24&#x02009;h were reported at doses &#x02265;50&#x02009;&#x003bc;g compared with placebo, with a clear dose&#x02212;response relationship. Mean changes in FEV<sub>1</sub> were 0.10&#x02009;l (95% CI 0.06, 0.14) and 0.12&#x02009;l (95% CI 0.08, 0.16) for 100&#x02009;&#x003bc;g and 200&#x02009;&#x003bc;g, respectively.</p></sec><sec><title>Conclusion</title><p>Single doses of EP-101 ranging from 12.5&#x02009;&#x003bc;g to 400&#x02009;&#x003bc;g were well tolerated. EP-101 delivered by high efficiency nebulizer device produced a rapid onset of bronchodilatation with clinically meaningful improvements in lung function maintained over a 24&#x02009;h period at all doses &#x0003e;50&#x02009;&#x003bc;g.</p></sec></abstract><kwd-group><kwd>COPD</kwd><kwd>EP-101</kwd><kwd>glycopyrrolate</kwd><kwd>LAMA</kwd><kwd>muscarinic antagonist</kwd><kwd>nebulizer</kwd></kwd-group></article-meta></front><body><boxed-text position="float"><sec><title>What is already known about this subject</title><list list-type="bullet"><list-item><p>
Long acting muscarinic antagonists, including tiotropium and glycopyrrolate, are a cornerstone of therapy in chronic obstructive pulmonary disease (COPD). EP-101 is a novel soluble glycopyrrolate formulation that can be delivered using an efficient nebulizer device.
</p></list-item></list></sec></boxed-text><boxed-text position="float"><sec><title>What this study adds</title><list list-type="bullet"><list-item><p>
This paper demonstrates dose related bronchodilatation following single dose administration of EP-101 in COPD patients, using a novel high efficiency nebulizer to deliver glycopyrrolate safely and effectively.
</p></list-item></list></sec></boxed-text><sec sec-type="intro"><title>Introduction</title><p>Muscarinic receptor antagonists (anticholinergics) play a central role in the management of chronic obstructive pulmonary disease (COPD) <xref rid="b1" ref-type="bibr">1</xref>&#x02013;<xref rid="b3" ref-type="bibr">3</xref>. Long acting muscarinic antagonists (LAMAs) provide effective bronchodilatation with a convenient dosing schedule. Glycopyrrolate is a LAMA that is kinetically selective for M<sub>1</sub>- and M<sub>3</sub>-receptors <xref rid="b4" ref-type="bibr">4</xref>, with a slow receptor dissociation time and has a quaternary ammonium structure <xref rid="b4" ref-type="bibr">4</xref>. It has long been approved for intravenous (i.v.) and intramuscular (i.m.) injection and oral formulations are also available. The safety of systemic glycopyrrolate bromide administration has been well documented over a 30 year period <xref rid="b5" ref-type="bibr">5</xref>,<xref rid="b6" ref-type="bibr">6</xref>. The safety of inhaled glycopyrrolate is also supported by extensive clinical studies with a dry powder formulation of this drug <xref rid="b7" ref-type="bibr">7</xref>.</p><p>A soluble formulation of glycopyrrolate bromide has been developed (EP-101) which can be delivered by nebulizer. Nebulizer delivery is an effective way to deliver drugs to COPD patients who have difficulty using inhalers, such as those with low inspiratory flow rates which make it difficult to use dry powder inhalers. The eFlow&#x000ae; PARI device (see Figure&#x02009;<xref ref-type="fig" rid="fig01">1</xref>) is a high efficiency nebulizer, which can be used to deliver EP-101 for the long term, maintenance treatment of patients with COPD. The eFlow&#x000ae; nebulizer system is able to deliver a wide range of drug volumes (0.5&#x02009;ml to 5&#x02009;ml) and dosages (0.01&#x02009;mg to 1000&#x02009;mg), allowing patients to take their treatment during consecutive breaths. The hole sizes can be adjusted from just below 2&#x02009;&#x003bc;m upwards.</p><fig id="fig01" position="float"><label>Figure 1</label><caption><p>A schematic of the aerosol production within the eFlow&#x000ae; nebulizer system</p></caption><graphic xlink:href="bcp0079-0492-f1"/></fig><p>This study investigated the dose&#x02212;response effects and duration of bronchodilatation of EP-101 administered using the eFlow&#x000ae; PARI device in patients with moderate to severe COPD. We also assessed the tolerability and pharmacokinetics of this formulation.</p></sec><sec sec-type="methods"><title>Methods</title><p>This was a two centre, randomized, placebo-controlled, double-blind, dose ranging, single dose, six way crossover study in patients with COPD of 40&#x02013;75 years of age. The study was approved by the North West 7 Research Ethics Committee &#x02013; Greater Central Manchester (10/H1008/36) and all subjects provided written informed consent.</p><sec><title>Study design</title><p>Subjects were eligible for the study if they had a clinical diagnosis of moderate to severe COPD with a post-bronchodilator FEV<sub>1</sub> 30&#x02013;70% of predicted normal at the screening visit. Patients were also required to demonstrate at least 12% and 150&#x02009;ml reversibility to inhaled ipratropium bromide. Eligible subjects participated in six treatment visits separated by washout periods of 5&#x02013;12 days. Subjects were randomized to receive a single dose of EP-101 (12.5&#x02009;&#x003bc;g, 25&#x02009;&#x003bc;g, 50&#x02009;&#x003bc;g, 100&#x02009;&#x003bc;g and 200&#x02009;&#x003bc;g) or placebo (between 08.00&#x02009;h and 09.00&#x02009;h) at each treatment visit. The study treatments (both active and placebo) were administered using the eFlow&#x000ae; nebulizer (PARI, Starnberg, Germany).</p><p>During each treatment visit the subject's pre-dose FEV<sub>1</sub> value was required to be within 15% of the pre-dose value at the first treatment visit, otherwise the visit was rescheduled. Study procedures during each treatment visit included serial spirometry at pre-dose, immediately following dosing (within 5&#x02009;min) and 15, 30&#x02009;min and 1, 2, 4, 6, 8, 10, 12, 14, 20, 23.5, 24, 27 and 30&#x02009;h post-dose. Blood samples were obtained to determine plasma glycopyrrolate concentrations at pre-dose and 5, 15, 30, 45 and 60&#x02009;min and 2, 4, 6, 8 and 12&#x02009;h post-dose in a subset of patients (<italic>n</italic> = 11). Heart rate, blood pressure and 12-lead electrocardiogram were obtained at pre-dose and 30 and 60&#x02009;min and 2, 6, 12 and 24&#x02009;h post-dose. Blood for biochemistry screening was taken at the screening visit and within 7 days following the last study treatment (safety follow-up visit).</p><p>Subjects were required to withhold any long acting &#x003b2;<sub>2</sub>-adrenoceptor agonists (LABA) bronchodilators for at least 24&#x02009;h and short acting bronchodilators (e.g. salbutamol, ipratropium or a combination) for at least 8&#x02009;h prior to receiving each study treatment. Inhaled LAMA (e.g. tiotropium bromide) was not permitted within 7 days prior to the screening visit and for the duration of the study and was replaced by inhaled ipratropium bromide. Inhaled corticosteroid use was permitted during the study provided that the steroid dose was stabilized for at least 6 weeks prior to the screening visit and throughout the study period. Rescue salbutamol was allowed for as-needed use any time during the study. However, if rescue salbutamol was used within 8&#x02009;h of the treatment visit, then the visit was rescheduled.</p></sec><sec><title>Lung function</title><p>Spirometry was performed in accordance with guidelines according to American Thoracic Society/European Respiratory Society standards <xref rid="b8" ref-type="bibr">8</xref>. For Caucasians of non-European descent and non-Caucasians, predicted values for FEV<sub>1</sub> and FVC were to be adjusted for race as per the European Coal and Steel Community (ECSC) guidelines <xref rid="b9" ref-type="bibr">9</xref>. Recordings were made with Vitalograph equipment (Buckingham, UK).</p></sec><sec><title>Laboratory analysis</title><p>Pharmacokinetic measurements of EP-101 were performed by Simbec Research Limited (Merthyr Tydfil, UK) using a validated liquid chromatography-tandem mass spectrometry (LC-MS-MS) method <xref rid="b10" ref-type="bibr">10</xref>. Data acquisition and integration were achieved using Applied Biosystems MDS Sciex Analyst software. The upper and lower limits of quantification were 10&#x02009;443.56&#x02009;pg&#x02009;ml<sup>&#x02212;1</sup> and 26.11&#x02009;pg&#x02009;ml<sup>&#x02212;1</sup>, respectively.</p></sec><sec><title>Statistical analysis</title><p>Analysis was performed on the intention-to-treat population. An analysis of covariance (<sc>ancova</sc>) with fixed effects for centre, treatment, period, sequence and a random effect for subject within sequence was used to calculate least square means using pre-dose FEV<sub>1</sub> as a covariate. For comparisons point estimates, 95% confidence intervals (CI) and <italic>P</italic> values for the difference between each EP-101 treatment <italic>vs.</italic> placebo were constructed using the residual mean square error obtained from the <sc>ancova</sc>, standardized FEV<sub>1</sub> and AUC were calculated using the linear trapezoidal rule (WinNonlin). The incidence of adverse events (AE) was compared between treatment groups with summary tables by treatment group, with descriptive statistics to summarize data.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patient characteristics</title><p>Patient demographics are shown in Table&#x02009;<xref ref-type="table" rid="tbl1">1</xref>. The patients had moderate to severe COPD (mean FEV<sub>1</sub> 54% predicted). Of the 42 subjects enrolled 35 completed the study, seven subjects were withdrawn, four due to adverse events including COPD exacerbations, two subjects were withdrawn for protocol non-compliance and one subject withdrew consent.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Patient demographics and summary of baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Demographics baseline (<italic>n</italic> = 42)</th><th align="center" rowspan="1" colspan="1">Mean</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Age (years) (SD)</bold></td><td align="center" rowspan="1" colspan="1">62.0 (7.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age range (years)</bold></td><td align="center" rowspan="1" colspan="1">44&#x02013;74</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Male, <italic>n</italic> (%)</bold></td><td align="center" rowspan="1" colspan="1">27 (64)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Female, <italic>n</italic> (%)</bold></td><td align="center" rowspan="1" colspan="1">15 (36)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Duration of COPD (years) (SD)</bold></td><td align="center" rowspan="1" colspan="1">7.5 (6.1)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Tobacco pack-years, mean (SD)</bold></td><td align="center" rowspan="1" colspan="1">42.9 (17.9)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Current smoker, <italic>n</italic> (%)</bold></td><td align="center" rowspan="1" colspan="1">24 (57)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ex-smoker, <italic>n</italic> (%)</bold></td><td align="center" rowspan="1" colspan="1">18 (43)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Currently using ICS, <italic>n</italic> (%)</bold></td><td align="center" rowspan="1" colspan="1">29 (69)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>No ICS use, <italic>n</italic> (%)</bold></td><td align="center" rowspan="1" colspan="1">13 (31)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Currently using ICS/LABA, <italic>n</italic> (%)</bold></td><td align="center" rowspan="1" colspan="1">27 (64)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FEV<sub>1</sub> pre-bronchodilator (l) (SD)</bold></td><td align="center" rowspan="1" colspan="1">1.21 (0.40)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FEV<sub>1</sub> pre-bronchodilator (% predicted), (SD)</bold></td><td align="center" rowspan="1" colspan="1">42.7 (11.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FEV<sub>1</sub> post-bronchodilator (l) (SD)</bold></td><td align="center" rowspan="1" colspan="1">1.52 (0.46)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FEV<sub>1</sub> post-bronchodilator (% predicted) (SD)</bold></td><td align="center" rowspan="1" colspan="1">53.8 (12.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FEV<sub>1</sub>/FVC post-bronchodilator (%) (SD)</bold></td><td align="center" rowspan="1" colspan="1">44.9 (11.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FEV<sub>1</sub> reversibility (ml) (SD)</bold></td><td align="center" rowspan="1" colspan="1">306 (119)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FEV<sub>1</sub> reversibility (%) (SD)</bold></td><td align="center" rowspan="1" colspan="1">27.3 (11.8)</td></tr></tbody></table></table-wrap></sec><sec><title>Pharmacodynamic response</title><p>At all tested doses there was rapid onset of response (at 5&#x02009;min, the first assessment) in FEV<sub>1</sub> and the response followed the normal circadian rhythm over the 24&#x02009;h period (Figure&#x02009;<xref ref-type="fig" rid="fig02">2</xref>). There was a dose&#x02212;response relationship in the time normalized FEV<sub>1</sub> (0&#x02013;24&#x02009;h; Figure&#x02009;<xref ref-type="fig" rid="fig03">3</xref>). The placebo-adjusted mean FEV<sub>1</sub> change from baseline at 24&#x02009;h post-dose (Figure&#x02009;<xref ref-type="fig" rid="fig04">4</xref>) also showed a dose&#x02212;response relationship, with statistically significant improvements observed at doses &#x02265;50&#x02009;&#x003bc;g. Clinically meaningful improvements &#x0003e;100&#x02009;ml for the placebo-adjusted FEV<sub>1</sub> improvements at 24&#x02009;h post-dose were observed at the 100&#x02009;&#x003bc;g and 200&#x02009;&#x003bc;g doses, suggesting sustained 24&#x02009;h bronchodilatation at these doses. Table&#x02009;<xref ref-type="table" rid="tbl2">2</xref> shows the placebo adjusted FEV<sub>1</sub> mean difference from pre-dose across the different doses, demonstrating dose&#x02013;response effects.</p><fig id="fig02" position="float"><label>Figure 2</label><caption><p>Mean change from baseline FEV<sub>1</sub> after different doses of nebulized glycopyrrolate. The first assessment at 5&#x02009;min post-dose is displayed at 0&#x02009;h. <inline-formula><inline-graphic xlink:href="bcp0079-0492-mu1.jpg" mimetype="image"/></inline-formula>, placebo; <inline-formula><inline-graphic xlink:href="bcp0079-0492-mu2.jpg" mimetype="image"/></inline-formula>, 12.5&#x02009;&#x003bc;g; <inline-formula><inline-graphic xlink:href="bcp0079-0492-mu3.jpg" mimetype="image"/></inline-formula>, 50&#x02009;&#x003bc;g; <inline-formula><inline-graphic xlink:href="bcp0079-0492-mu4.jpg" mimetype="image"/></inline-formula>, 100&#x02009;&#x003bc;g; <inline-formula><inline-graphic xlink:href="bcp0079-0492-mu5.jpg" mimetype="image"/></inline-formula>, 200&#x02009;&#x003bc;g; <inline-formula><inline-graphic xlink:href="bcp0079-0492-mu6.jpg" mimetype="image"/></inline-formula>, 400&#x02009;&#x003bc;g</p></caption><graphic xlink:href="bcp0079-0492-f2"/></fig><fig id="fig03" position="float"><label>Figure 3</label><caption><p>Standardized (time normalized) FEV<sub>1</sub> (0&#x02013;24&#x02009;h) (ITT population; mean&#x02009;&#x000b1;&#x02009;SEM). <italic>n</italic> = 37&#x02013;39</p></caption><graphic xlink:href="bcp0079-0492-f3"/></fig><fig id="fig04" position="float"><label>Figure 4</label><caption><p>Placebo-adjusted FEV<sub>1</sub> at 24&#x02009;h (ITT population; mean &#x000b1; SEM) after different doses of nebulized glycopyrrolate. *<italic>P</italic> &#x0003c; 0.001 <sc>ancova</sc>. <italic>n</italic> = 37&#x02013;39</p></caption><graphic xlink:href="bcp0079-0492-f4"/></fig><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Statistical analysis of change from pre-dose in FEV<sub>1</sub> through 24&#x02009;h post-dose compared with placebo group (ITT population); Least square mean difference from pre-dose FEV<sub>1</sub> (95% CI) all values <italic>P</italic> &#x0003c; 0.001; <sup>*</sup><italic>P</italic> &#x0003c; 0.01; NS not significant. <italic>n</italic> = 37 for placebo, <italic>n</italic> values for each dose are stated in the table</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Time</th><th align="center" colspan="5" rowspan="1">Dose (&#x003bc;g 0.5&#x02009;ml<sup>&#x02013;1</sup>)</th></tr><tr><th align="left" rowspan="1" colspan="1">12.5 &#x02013; placebo (<italic>n</italic> = 39)</th><th align="left" rowspan="1" colspan="1">50 &#x02013; placebo (<italic>n</italic> = 38)</th><th align="left" rowspan="1" colspan="1">100 &#x02013; placebo (<italic>n</italic> = 37)</th><th align="left" rowspan="1" colspan="1">200 &#x02013; placebo (<italic>n</italic> = 37)</th><th align="left" rowspan="1" colspan="1">400 &#x02013; placebo (<italic>n</italic> = 37)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>5&#x02009;min</bold></td><td align="left" rowspan="1" colspan="1">0.06 (0.03&#x02013;0.09)</td><td align="left" rowspan="1" colspan="1">0.08 (0.04&#x02013;0.11)</td><td align="left" rowspan="1" colspan="1">0.10 (0.07&#x02013;0.13)</td><td align="left" rowspan="1" colspan="1">0.13 (0.1&#x02013;0.16)</td><td align="left" rowspan="1" colspan="1">0.14 (0.11&#x02013;0.17)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>15&#x02009;min</bold></td><td align="left" rowspan="1" colspan="1">0.10 (0.06&#x02013;0.14)</td><td align="left" rowspan="1" colspan="1">0.15 (0.11&#x02013;0.19)</td><td align="left" rowspan="1" colspan="1">0.17 (0.13&#x02013;0.21)</td><td align="left" rowspan="1" colspan="1">0.21 (0.17&#x02013;0.25)</td><td align="left" rowspan="1" colspan="1">0.21 (0.17&#x02013;0.25)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>30&#x02009;min</bold></td><td align="left" rowspan="1" colspan="1">0.10 (0.07&#x02013;0.14)</td><td align="left" rowspan="1" colspan="1">0.17 (0.14&#x02013;0.21)</td><td align="left" rowspan="1" colspan="1">0.21 (0.17&#x02013;0.24)</td><td align="left" rowspan="1" colspan="1">0.22 (0.18&#x02013;0.26)</td><td align="left" rowspan="1" colspan="1">0.23 (0.20&#x02013;0.27)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>1&#x02009;h</bold></td><td align="left" rowspan="1" colspan="1">0.13 (0.09&#x02013;0.17)</td><td align="left" rowspan="1" colspan="1">0.20 (0.16&#x02013;0.24)</td><td align="left" rowspan="1" colspan="1">0.21 (0.17&#x02013;0.25)</td><td align="left" rowspan="1" colspan="1">0.23 (0.20&#x02013;0.27)</td><td align="left" rowspan="1" colspan="1">0.23 (0.19&#x02013;0.27)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>2&#x02009;h</bold></td><td align="left" rowspan="1" colspan="1">0.13 (0.08&#x02013;0.17)</td><td align="left" rowspan="1" colspan="1">0.20 (0.16&#x02013;0.25)</td><td align="left" rowspan="1" colspan="1">0.21 (0.17&#x02013;0.26)</td><td align="left" rowspan="1" colspan="1">0.24 (0.19&#x02013;0.28)</td><td align="left" rowspan="1" colspan="1">0.22 (0.18&#x02013;0.26)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>4&#x02009;h</bold></td><td align="left" rowspan="1" colspan="1">0.07 (0.02&#x02013;0.11)<sup>*</sup></td><td align="left" rowspan="1" colspan="1">0.15 (0.10&#x02013;0.19)</td><td align="left" rowspan="1" colspan="1">0.16 (0.12&#x02013;0.21)</td><td align="left" rowspan="1" colspan="1">0.21 (0.16&#x02013;0.26)</td><td align="left" rowspan="1" colspan="1">0.19 (0.15&#x02013;0.24)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>8&#x02009;h</bold></td><td align="left" rowspan="1" colspan="1">0.08 (0.03&#x02013;0.12)</td><td align="left" rowspan="1" colspan="1">0.14 (0.10&#x02013;0.18)</td><td align="left" rowspan="1" colspan="1">0.13 (0.09&#x02013;0.18)</td><td align="left" rowspan="1" colspan="1">0.19 (0.15&#x02013;0.24)</td><td align="left" rowspan="1" colspan="1">0.20 (0.15&#x02013;0.24)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>12&#x02009;h</bold></td><td align="left" rowspan="1" colspan="1">0.07 (0.02&#x02013;0.11)<sup>*</sup></td><td align="left" rowspan="1" colspan="1">0.15 (0.10&#x02013;0.19)</td><td align="left" rowspan="1" colspan="1">0.12 (0.07&#x02013;0.17)</td><td align="left" rowspan="1" colspan="1">0.19 (0.14&#x02013;0.23)</td><td align="left" rowspan="1" colspan="1">0.17 (0.13&#x02013;0.22)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>24&#x02009;h</bold></td><td align="left" rowspan="1" colspan="1">0.04 (&#x02212;0.01&#x02013;0.08) NS</td><td align="left" rowspan="1" colspan="1">0.07 (0.03&#x02013;0.11)</td><td align="left" rowspan="1" colspan="1">0.10 (0.06&#x02013;0.14)</td><td align="left" rowspan="1" colspan="1">0.12 (0.08&#x02013;0.16)</td><td align="left" rowspan="1" colspan="1">0.10 (0.06&#x02013;0.14)</td></tr></tbody></table></table-wrap></sec><sec><title>Safety</title><p>Single doses of EP-101 were well tolerated (Table&#x02009;<xref ref-type="table" rid="tbl3">3</xref>) with comparable AE profiles to placebo. There were no clinically significant differences from placebo in heart rate, blood pressure and ECG parameters, including QT<sub>c</sub>.</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Number and frequency of spontaneously reported adverse events. The percentage of subjects who reported adverse events was similar comparing EP-101 and placebo treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1"/><th align="center" colspan="5" rowspan="1">EP-101 doses</th></tr><tr><th align="left" rowspan="1" colspan="1">Patients<break/><italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Placebo<break/><italic>n</italic> = 37</th><th align="left" rowspan="1" colspan="1">12.5&#x02009;&#x003bc;g<break/><italic>n</italic> = 39</th><th align="left" rowspan="1" colspan="1">50&#x02009;&#x003bc;g<break/><italic>n</italic> = 38</th><th align="left" rowspan="1" colspan="1">100&#x02009;&#x003bc;g<break/><italic>n</italic> = 37</th><th align="left" rowspan="1" colspan="1">200&#x02009;&#x003bc;g<break/><italic>n</italic> = 37</th><th align="left" rowspan="1" colspan="1">400&#x02009;&#x003bc;g<break/><italic>n</italic> = 37</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Total</bold></td><td align="left" rowspan="1" colspan="1">14 (38)</td><td align="left" rowspan="1" colspan="1">16 (41)</td><td align="left" rowspan="1" colspan="1">14 (37)</td><td align="left" rowspan="1" colspan="1">17 (46)</td><td align="left" rowspan="1" colspan="1">15 (41)</td><td align="left" rowspan="1" colspan="1">13 (35)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Skin injury</bold></td><td align="left" rowspan="1" colspan="1">2 (6)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Headache</bold></td><td align="left" rowspan="1" colspan="1">4 (11)</td><td align="left" rowspan="1" colspan="1">6 (3)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>COPD</bold></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (5)</td><td align="left" rowspan="1" colspan="1">1 (3)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Cough</bold></td><td align="left" rowspan="1" colspan="1">5 (14)</td><td align="left" rowspan="1" colspan="1">2 (5)</td><td align="left" rowspan="1" colspan="1">2 (5)</td><td align="left" rowspan="1" colspan="1">5 (14)</td><td align="left" rowspan="1" colspan="1">3 (8)</td><td align="left" rowspan="1" colspan="1">3 (8)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Dyspnoea</bold></td><td align="left" rowspan="1" colspan="1">2 (5)</td><td align="left" rowspan="1" colspan="1">2 (5)</td><td align="left" rowspan="1" colspan="1">2 (5)</td><td align="left" rowspan="1" colspan="1">1 (4)</td><td align="left" rowspan="1" colspan="1">1 (3)</td><td align="left" rowspan="1" colspan="1">1 (3)</td></tr></tbody></table></table-wrap></sec><sec><title>Pharmacokinetics</title><p>The mean delivery time for all doses of EP-101 was less than 2&#x02009;min (range 1.6&#x02212;1.9) and EP-101 was rapidly absorbed with peak plasma concentrations within 15&#x02013;30&#x02009;min. Systemic exposure of EP-101 showed a dose-proportional increase in <italic>C</italic><sub>max</sub> over the dose range 12.5&#x02013;400&#x02009;&#x003bc;g. There were only two measurable plasma glycopyrrolate concentrations available at the 12.5&#x02009;&#x003bc;g dose level. Therefore, 12.5&#x02009;&#x003bc;g was not included in the dose proportionality analysis (Figure&#x02009;<xref ref-type="fig" rid="fig05">5</xref>, Table&#x02009;<xref ref-type="table" rid="tbl4">4</xref>).</p><fig id="fig05" position="float"><label>Figure 5</label><caption><p>Plasma glycopyrrolate concentrations after different doses. <inline-formula><inline-graphic xlink:href="bcp0079-0492-mu7.jpg" mimetype="image"/></inline-formula>, 12.5&#x02009;&#x003bc;g; <inline-formula><inline-graphic xlink:href="bcp0079-0492-mu8.jpg" mimetype="image"/></inline-formula>, 50&#x02009;&#x003bc;g; <inline-formula><inline-graphic xlink:href="bcp0079-0492-mu9.jpg" mimetype="image"/></inline-formula>, 100&#x02009;&#x003bc;g; <inline-formula><inline-graphic xlink:href="bcp0079-0492-mu10.jpg" mimetype="image"/></inline-formula>, 200&#x02009;&#x003bc;g; <inline-formula><inline-graphic xlink:href="bcp0079-0492-mu11.jpg" mimetype="image"/></inline-formula>, 400&#x02009;&#x003bc;g</p></caption><graphic xlink:href="bcp0079-0492-f5"/></fig><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p>Pharmacokinetics summary table. Data are mean (SD) except for <italic>t</italic><sub>max</sub> (min&#x02212;max)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Doses</th><th align="center" rowspan="1" colspan="1"><italic>C</italic><sub>max</sub> (pg ml<sup>&#x02212;1</sup>)</th><th align="left" rowspan="1" colspan="1"><italic>t</italic><sub>max</sub> (h)</th><th align="left" rowspan="1" colspan="1"><italic>t</italic><sub>1/2</sub> (h)</th><th align="center" rowspan="1" colspan="1">AUC(0,<italic>t</italic>) (pg mL<sup>&#x02212;1</sup>&#x02009;h)</th><th align="center" rowspan="1" colspan="1">AUC(0,&#x0221e;) (pg mL<sup>&#x02212;1</sup>&#x02009;h)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>50&#x02009;&#x003bc;g (<italic>n</italic> = 13)</bold></td><td align="center" rowspan="1" colspan="1">87 (52)</td><td align="left" rowspan="1" colspan="1">0.32 (0.015-0.35)</td><td align="left" rowspan="1" colspan="1">0.9 (0.02)</td><td align="center" rowspan="1" colspan="1">101 (81)</td><td align="center" rowspan="1" colspan="1">255 (91)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>100&#x02009;&#x003bc;g (<italic>n</italic> = 12)</bold></td><td align="center" rowspan="1" colspan="1">162 (82)</td><td align="left" rowspan="1" colspan="1">0.26 (0.015-0.33)</td><td align="left" rowspan="1" colspan="1">3.3 (1.2)</td><td align="center" rowspan="1" colspan="1">306 (194)</td><td align="center" rowspan="1" colspan="1">659 (188)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>200&#x02009;&#x003bc;g (<italic>n</italic> = 12)</bold></td><td align="center" rowspan="1" colspan="1">347 (155)</td><td align="left" rowspan="1" colspan="1">0.28 (0.15-0.38)</td><td align="left" rowspan="1" colspan="1">3.4 (1.3)</td><td align="center" rowspan="1" colspan="1">797 (505)</td><td align="center" rowspan="1" colspan="1">796 (217)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>400&#x02009;&#x003bc;g (<italic>n</italic> = 13)</bold></td><td align="center" rowspan="1" colspan="1">566 (269)</td><td align="left" rowspan="1" colspan="1">0.18 (0.15-0.32)</td><td align="left" rowspan="1" colspan="1">4.8 (3.0)</td><td align="center" rowspan="1" colspan="1">1805 (1008)</td><td align="center" rowspan="1" colspan="1">1642 (1077)</td></tr></tbody></table></table-wrap><p>The elimination half-life (<italic>t</italic><sub>1/2</sub>) of glycopyrrolate was calculated for the 0&#x02013;1&#x02009;h and 0&#x02013;12&#x02009;h intervals. The median <italic>t</italic><sub>1/2,</sub>0&#x02212;1h ranged from 1.10&#x02212;1.15&#x02009;h and median <italic>t</italic><sub>1/2,</sub> 0&#x02013;12&#x02009;h ranged from 2.30&#x02212;7.45&#x02009;h following administration of 50, 100, 200 and 400&#x02009;&#x003bc;g, respectively.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>COPD is characterized by chronic inflammation of the airways and lung parenchyma, which causes chronic airflow limitation due to a mixture of small airway disease and parenchymal destruction, resulting in air trapping and hyperinflation. Unlike asthma, airflow limitation is progressive and is not fully reversible <xref rid="b11" ref-type="bibr">11</xref>,<xref rid="b12" ref-type="bibr">12</xref>. LAMA alone <xref rid="b13" ref-type="bibr">13</xref> or in combination with LABA <xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b14" ref-type="bibr">14</xref>,<xref rid="b15" ref-type="bibr">15</xref> or in triple therapy with inhaled corticosteroids (LABA/LAMA/ICS) <xref rid="b16" ref-type="bibr">16</xref> are well established treatments for COPD. Vagal cholinergic tone has a greater effect on airway resistance in airways narrowed by fixed obstruction and blocking of this cholinergic bronchoconstriction reduces airway resistance and in peripheral airways reduces air trapping <xref rid="b1" ref-type="bibr">1</xref>. The bronchoconstrictor effect of acetylcholine is mediated mainly through M<sub>3</sub>-muscarinic receptors on airway smooth muscle cells, whereas M<sub>1</sub>-receptors enhance cholinergic reflexes. By contrast M<sub>2</sub>-receptors on cholinergic nerve endings inhibit acetylcholine release and should not be blocked. Anticholinergics, such as tiotropium and glycopyrrolate, which selectively block M<sub>1</sub> and M<sub>3</sub> receptors are therefore preferable to non-selective muscarinic antagonists, such as atropine and ipratropium bromide, that also block M<sub>2</sub> receptors <xref rid="b17" ref-type="bibr">17</xref>,<xref rid="b18" ref-type="bibr">18</xref>. Both glycopyrrolate and tiotropium are kinetically selective for M<sub>1</sub> and M<sub>3</sub> receptors and have a similar duration of action with slow dissociation for these receptor subtypes <xref rid="b4" ref-type="bibr">4</xref>,<xref rid="b19" ref-type="bibr">19</xref>,<xref rid="b20" ref-type="bibr">20</xref>. The slow dissociation profile of glycopyrrolate contributes to the long duration of action seen in this and other clinical studies <xref rid="b21" ref-type="bibr">21</xref>. By contrast there is a much more rapid dissociation from M<sub>2</sub> receptors and this kinetic selectivity avoids prolonged blockade of pre-synaptic M<sub>2</sub> receptors thus reducing the increased release of acetylcholine which may antagonize the bronchodilator effect of blocking the M<sub>3</sub> receptors.</p><p>A dose-related and clinically significant improvement in FEV<sub>1</sub> following nebulized EP-101 at 24&#x02009;h indicates that this drug causes lung function improvements that are present for up to 24&#x02009;h after dosing. The bronchodilatation observed is consistent with a local site specific effect <xref rid="b1" ref-type="bibr">1</xref>. The magnitude of the placebo-adjusted FEV<sub>1</sub> improvement at 24&#x02009;h post-dose in this study was &#x0003e;100&#x02009;ml at both the 100&#x02009;&#x003bc;g and 200&#x02009;&#x003bc;g doses (Figure&#x02009;<xref ref-type="fig" rid="fig04">4</xref>). Extrapolating from clinical trial data <xref rid="b22" ref-type="bibr">22</xref> &#x0003e;100&#x02009;ml change is felt to be clinically meaningful. The bronchodilator effect persists at 24&#x02009;h despite low trough concentrations of drug, explained previously by the receptor profile of glycopyrrolate.</p><p>Single doses of EP-101 delivered via the investigational eFlow&#x000ae; nebulizer were safe and well tolerated. There were no clinically relevant significant changes in vital signs and ECG parameters, and there was an absence of the typical muscarinic side effects, such as dry mouth and increased heart rate, although this was a single dose study and these data need to be interpreted with caution. Currently available anti-cholinergic drugs all contain a quaternary ammonium, which is why these drugs do not penetrate the blood brain barrier and have a lower systemic absorption and more favourable adverse event profile then their predecessor atropine, which had considerable CNS side effects <xref rid="b18" ref-type="bibr">18</xref>.</p><p>The first reported study using nebulized glycopyrrolate described bronchodilatation following methacholine challenge in asthma <xref rid="b21" ref-type="bibr">21</xref>. Subsequently glycopyrrolate has been developed as a single agent <xref rid="b21" ref-type="bibr">21</xref>,<xref rid="b23" ref-type="bibr">23</xref>,<xref rid="b24" ref-type="bibr">24</xref>, in combination with LABA <xref rid="b25" ref-type="bibr">25</xref>&#x02013;<xref rid="b27" ref-type="bibr">27</xref>, or triple therapy in combination with LABA, LAMA and ICS <xref rid="b28" ref-type="bibr">28</xref>,<xref rid="b29" ref-type="bibr">29</xref> for the treatment of both asthma and COPD. A potential disadvantage of fixed dose combination therapies may be that the fixed daily dose of glycopyrrolate is 50&#x02009;&#x003bc;g or less. The dose&#x02212;response to FEV<sub>1</sub> suggests that the optimal dose of glycopyrrolate should be at least 100&#x02009;&#x003bc;g, which corresponds to &#x00394;FEV<sub>1</sub> &#x0003e; 100&#x02009;ml <xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b30" ref-type="bibr">30</xref>.</p><p>Tiotropium (Spiriva) is available as a single dose dry powder inhaler (DPI; Handihaler) and a soft mist inhaler (Respimat), whereas glycopyrrolate (Seebri) is available (in the EU only) as a dry powder inhaler. Neither of these marketed drugs is available for nebulized treatment. Tiotropium is only poorly soluble and not suitable for nebulization. While metered dose inhalers (MDIs) and DPIs are the most widely prescribed medications for COPD patients, up to 75% of COPD patients do not receive an optimal dose from inhalers due to poor coordination, an inability to inhale rapidly and forcefully, an inability to hold their breath for the allotted time (up to 10&#x02009;s) after the dose, and exhalation into the device before or after the dose delivery <xref rid="b31" ref-type="bibr">31</xref>,<xref rid="b32" ref-type="bibr">32</xref>. Delivery by nebulization provides an effective alternative for those patients who experience difficulties using an MDI or DPI device. Generally these patients tend to be older, more debilitated and more severely obstructed patients. These patients may find nebulizer delivery of their medications to be more effective since an optimal dose is delivered by normal (tidal) breathing, regardless of disease state <xref rid="b33" ref-type="bibr">33</xref>,<xref rid="b34" ref-type="bibr">34</xref>.</p><p>Currently available bronchodilatation medication for nebulization are short acting muscarinic antagonists (ipratropium bromide) <xref rid="b35" ref-type="bibr">35</xref>, short acting &#x003b2;<sub>2</sub>-adrenoceptor agonists (salbutamol, terbutaline) and long acting &#x003b2;<sub>2</sub>-adrenoceptor agonists (formoterol, salmeterol, indacaterol) <xref rid="b35" ref-type="bibr">35</xref>, as well as a combination of ipratropium bromide and salbutamol (DuoNeB&#x000ae;). The short acting bronchodilators require two or four treatments a day when administered via a general purpose jet nebulizer. These medications also require 10&#x02013;15&#x02009;min administration time per dose, which is likely to result in lower compliance. Patients are also burdened with large, non-portable general purpose nebulizers that can take up to 10&#x02013;15&#x02009;min to deliver each dose. These frequent, long treatments are inconvenient, making it difficult for the patient to accept and be compliant with treatment. Therefore, COPD patients who rely on nebulized treatment would benefit from a LAMA delivered by a portable nebulizer over a shorter treatment time. This form of delivery may also be appropriate for the treatment of acute exacerbations in the future. The mean delivery time for all doses of EP-101 was less than 2&#x02009;min (range 1.6&#x02013;1.9&#x02009;min), a rapid delivery that compares very favourably with general purpose nebulizers. This delivery using a high efficiency nebulizer (eFlow&#x000ae; system, PARI) also facilitates for the long term, maintenance treatment. The nebulizer device may be used once daily or if preferred as a twice daily regimen to enhance bronchodilatation and reduce side effect profile (by lowering <italic>C</italic><sub>max</sub>). The eFlow&#x000ae; nebulizer (see Figure&#x02009;<xref ref-type="fig" rid="fig01">1</xref>) provides glycopyrrolate as fine-sized droplets with a mass median diameter (MMD) of approximately 3.5 microns and a smaller geometric standard deviation (GSD) of approximately 1.5 with better delivery to peripheral airways and more homogenous distribution in the lungs than with standard nebulizer delivery systems. The <italic>in vitro</italic> lung dose is also increased more than three-fold by using the eFlow&#x000ae; nebulizer compared with general purpose nebulizers.</p><p>Mucus secretion is largely mediated by M<sub>3</sub>- receptors and M<sub>3</sub>-receptor blockade may also reduce mucus hypersecretion <xref rid="b18" ref-type="bibr">18</xref>,<xref rid="b36" ref-type="bibr">36</xref>. Recent studies have demonstrated an anti-inflammatory action of muscarinic antagonists which includes abrogation of animal models of allergen challenge <xref rid="b4" ref-type="bibr">4</xref>, reduction in neutrophil elastase activity <xref rid="b37" ref-type="bibr">37</xref> and modification of growth factors, such as EGF and TGF&#x003b2; <xref rid="b38" ref-type="bibr">38</xref>,<xref rid="b39" ref-type="bibr">39</xref>. Airway remodelling in COPD correlates with disease severity <xref rid="b40" ref-type="bibr">40</xref> and both neuronal and non-neuronal acetylcholine and muscarinic receptors appear to be involved in inflammation which suggests a potential long term benefit for LAMA therapy in COPD <xref rid="b41" ref-type="bibr">41</xref>&#x02013;<xref rid="b43" ref-type="bibr">43</xref>.</p><p>In conclusion EP-101 delivered via the investigational eFlow&#x000ae; nebulizer was safe and well tolerated, with no significant changes in cardiovascular signs and ECG parameters. There was a dose-related and clinically significant improvement in FEV<sub>1</sub> following nebulized EP-101. EP-101 showed linear pharmacokinetics with dose proportionality over the 12.5&#x02013;400&#x02009;&#x003bc;g dose range. This study together provides support for development of EP-101 as a convenient nebulized LAMA bronchodilator for COPD patients.</p></sec><sec><title>Competing Interests</title><p>All authors have completed the Unified Competing Interest form at <ext-link ext-link-type="uri" xlink:href="http://www.icmje.org/coi_disclosure.pdf">http://www.icmje.org/coi_disclosure.pdf</ext-link> (available on request from the corresponding author) and declare the study received funding from Elevation Pharmaceuticals Inc., now incorporated with Sunovion Pharmaceuticals Inc. BRL has received research funding from AstraZeneca and Pfizer in the previous 3 years. PJB has served on Scientific Advisory Boards of AstraZeneca, Boehringer-Ingelheim, Chiesi, Daiichi-Sankyo, GlaxoSmithKline, Novartis, Nycomed, Pfizer, Teva and UCB and has received research funding from Aquinox Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Chiesi, Daiichi-Sankyo, GlaxoSmithKline, Novartis, Nycomed, Pfizer and Prosonix. He is also a cofounder of RespiVert (now part of Johnson &#x00026; Johnson) which has discovered novel inhaled anti-inflammatory treatments for asthma and COPD. CRJ has had no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years. AT was an employee of Elevation Pharmaceuticals when the study was conducted. DS has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards and research grants from various pharmaceutical companies including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, CIPLA, Forest, Genetech, GlaxoSmithKline, Merck, Novartis, Pfizer and Takeda in the previous 3 years. There are no other relationships or activities that could appear to have influenced the submitted work.</p><p>This work was funded by Elevation Pharmaceuticals Inc., now incorporated with Sunovion Pharmaceuticals Inc.</p></sec></body><back><ref-list><title>References</title><ref id="b1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>NJ</given-names></name></person-group><article-title>Anticholinergic agents in COPD</article-title><source>Chest</source><year>1987</year><volume>91</volume><fpage>52S</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">3552471</pub-id></element-citation></ref><ref id="b2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>The role of anticholinergics in chronic obstructive pulmonary disease</article-title><source>Am J Med</source><year>2004</year><volume>117</volume><issue>Suppl. 12A</issue><fpage>24S</fpage><lpage>32S</lpage><pub-id pub-id-type="pmid">15693640</pub-id></element-citation></ref><ref id="b3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koarai</surname><given-names>A</given-names></name><name><surname>Traves</surname><given-names>SL</given-names></name><name><surname>Fenwick</surname><given-names>PS</given-names></name><name><surname>Brown</surname><given-names>SM</given-names></name><name><surname>Chana</surname><given-names>KK</given-names></name><name><surname>Russell</surname><given-names>RE</given-names></name><name><surname>Nicholson</surname><given-names>AG</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Donnelly</surname><given-names>LE</given-names></name></person-group><article-title>Expression of muscarinic receptors by human macrophages</article-title><source>Eur Respir J</source><year>2012</year><volume>39</volume><fpage>698</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">21885397</pub-id></element-citation></ref><ref id="b4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>EB</given-names></name><name><surname>Patel</surname><given-names>H</given-names></name><name><surname>Keeling</surname><given-names>JE</given-names></name><name><surname>Yacoub</surname><given-names>MH</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Belvisi</surname><given-names>MG</given-names></name></person-group><article-title>Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways</article-title><source>Br J Pharmacol</source><year>1999</year><volume>127</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">10385241</pub-id></element-citation></ref><ref id="b5"><element-citation publication-type="book"><collab>Baxter Healthcare Corporation</collab><source>Robinul&#x000ae; Injection [Package Insert]</source><year>2006</year><publisher-loc>Deerfield, IL</publisher-loc><publisher-name>Baxter Healthcare Corporation</publisher-name></element-citation></ref><ref id="b6"><element-citation publication-type="other"><year>1974</year><comment>NDA 17-558 Pharmacology Review: FDA centre for drug evaluation and research</comment></element-citation></ref><ref id="b7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Noord</surname><given-names>JA</given-names></name><name><surname>Buhl</surname><given-names>R</given-names></name><name><surname>Laforce</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>F</given-names></name><name><surname>Dolker</surname><given-names>M</given-names></name><name><surname>Overend</surname><given-names>T</given-names></name></person-group><article-title>QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>2010</year><volume>65</volume><fpage>1086</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">20978028</pub-id></element-citation></ref><ref id="b8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MR</given-names></name><name><surname>Hankinson</surname><given-names>J</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name><name><surname>Burgos</surname><given-names>F</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Coates</surname><given-names>A</given-names></name><name><surname>Crapo</surname><given-names>R</given-names></name><name><surname>Enright</surname><given-names>P</given-names></name><name><surname>van der Grinten</surname><given-names>CP</given-names></name><name><surname>Gustafsson</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>DC</given-names></name><name><surname>MacIntyre</surname><given-names>N</given-names></name><name><surname>McKay</surname><given-names>R</given-names></name><name><surname>Navajas</surname><given-names>D</given-names></name><name><surname>Pedersen</surname><given-names>OF</given-names></name><name><surname>Pellegrino</surname><given-names>R</given-names></name><name><surname>Viegi</surname><given-names>G</given-names></name><name><surname>Wanger</surname><given-names>J</given-names></name><name><surname>Force</surname><given-names>AET</given-names></name></person-group><article-title>Standardisation of spirometry</article-title><source>Eur Respir J</source><year>2005</year><volume>26</volume><fpage>319</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">16055882</pub-id></element-citation></ref><ref id="b9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quanjer</surname><given-names>PH</given-names></name><name><surname>Tammeling</surname><given-names>GJ</given-names></name><name><surname>Cotes</surname><given-names>JE</given-names></name><name><surname>Pedersen</surname><given-names>OF</given-names></name><name><surname>Peslin</surname><given-names>R</given-names></name><name><surname>Yernault</surname><given-names>JC</given-names></name></person-group><article-title>Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official statement of the European Respiratory Society</article-title><source>Eur Respir J Suppl</source><year>1993</year><volume>16</volume><fpage>5</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">8499054</pub-id></element-citation></ref><ref id="b10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tutuncu</surname><given-names>A</given-names></name><name><surname>Leaker</surname><given-names>B</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name></person-group><article-title>Dose-ranging study to assess the safety and pharmacokinetic profile of nebulized glycopyrrolate (EP-101) using high efficiency nebulizer in COPD patients</article-title><source>Am J Respir Crit Care Med</source><year>2012</year><volume>185</volume><fpage>A2914</fpage></element-citation></ref><ref id="b11"><element-citation publication-type="other"><collab>Global Initiative for Chronic Obstructive Lung Disease</collab><year>2007</year><comment>Global strategy for the diagnosis, management and prevention of COPD</comment></element-citation></ref><ref id="b12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Hurd</surname><given-names>S</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Buist</surname><given-names>SA</given-names></name><name><surname>Calverley</surname><given-names>P</given-names></name><name><surname>Fukuchi</surname><given-names>Y</given-names></name><name><surname>Jenkins</surname><given-names>C</given-names></name><name><surname>Rodriguez-Roisin</surname><given-names>R</given-names></name><name><surname>van Weel</surname><given-names>C</given-names></name><name><surname>Zielinski</surname><given-names>J</given-names></name></person-group><collab>Disease GIfCOL</collab><article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>176</volume><fpage>532</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">17507545</pub-id></element-citation></ref><ref id="b13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donohue</surname><given-names>JF</given-names></name></person-group><article-title>Therapeutic responses in asthma and COPD. Bronchodilators</article-title><source>Chest</source><year>2004</year><volume>126</volume><fpage>125S</fpage><lpage>137</lpage><comment>discussion 159S&#x02013;161S</comment><pub-id pub-id-type="pmid">15302773</pub-id></element-citation></ref><ref id="b14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rennard</surname><given-names>S</given-names></name><name><surname>Bantje</surname><given-names>T</given-names></name><name><surname>Centanni</surname><given-names>S</given-names></name><name><surname>Chanez</surname><given-names>P</given-names></name><name><surname>Chuchalin</surname><given-names>A</given-names></name><name><surname>D'Urzo</surname><given-names>A</given-names></name><name><surname>Kornmann</surname><given-names>O</given-names></name><name><surname>Perry</surname><given-names>S</given-names></name><name><surname>Jack</surname><given-names>D</given-names></name><name><surname>Owen</surname><given-names>R</given-names></name><name><surname>Higgins</surname><given-names>M</given-names></name></person-group><article-title>A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison</article-title><source>Respir Med</source><year>2008</year><volume>102</volume><fpage>1033</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">18479895</pub-id></element-citation></ref><ref id="b15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tashkin</surname><given-names>DP</given-names></name><name><surname>Pearle</surname><given-names>J</given-names></name><name><surname>Iezzoni</surname><given-names>D</given-names></name><name><surname>Varghese</surname><given-names>ST</given-names></name></person-group><article-title>Formoterol and tiotropium compared with tiotropium alone for treatment of COPD</article-title><source>COPD</source><year>2009</year><volume>6</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">19229704</pub-id></element-citation></ref><ref id="b16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Brooks</surname><given-names>J</given-names></name><name><surname>Hagan</surname><given-names>G</given-names></name><name><surname>Cahn</surname><given-names>A</given-names></name><name><surname>O'Connor</surname><given-names>BJ</given-names></name></person-group><article-title>Superiority of &#x02018;triple&#x02019; therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD</article-title><source>Thorax</source><year>2008</year><volume>63</volume><fpage>592</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">18245142</pub-id></element-citation></ref><ref id="b17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansel</surname><given-names>TT</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD</article-title><source>Drugs Today (Barc)</source><year>2002</year><volume>38</volume><fpage>585</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">12582447</pub-id></element-citation></ref><ref id="b18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Restrepo</surname><given-names>RD</given-names></name></person-group><article-title>Use of inhaled anticholinergic agents in obstructive airway disease</article-title><source>Respir Care</source><year>2007</year><volume>52</volume><fpage>833</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">17594728</pub-id></element-citation></ref><ref id="b19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koumis</surname><given-names>T</given-names></name><name><surname>Samuel</surname><given-names>S</given-names></name></person-group><article-title>Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease</article-title><source>Clin Ther</source><year>2005</year><volume>27</volume><fpage>377</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">15922812</pub-id></element-citation></ref><ref id="b20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villetti</surname><given-names>G</given-names></name><name><surname>Bergamaschi</surname><given-names>M</given-names></name><name><surname>Bassani</surname><given-names>F</given-names></name><name><surname>Bolzoni</surname><given-names>PT</given-names></name><name><surname>Harrison</surname><given-names>S</given-names></name><name><surname>Gigli</surname><given-names>PM</given-names></name><name><surname>Janni</surname><given-names>A</given-names></name><name><surname>Geppetti</surname><given-names>P</given-names></name><name><surname>Civelli</surname><given-names>M</given-names></name><name><surname>Patacchini</surname><given-names>R</given-names></name></person-group><article-title>Pharmacological assessment of the duration of action of glycopyrrolate <italic>vs</italic>. tiotropium and ipratropium in guinea-pig and human airways</article-title><source>Br J Pharmacol</source><year>2006</year><volume>148</volume><fpage>291</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">16565730</pub-id></element-citation></ref><ref id="b21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansel</surname><given-names>TT</given-names></name><name><surname>Neighbour</surname><given-names>H</given-names></name><name><surname>Erin</surname><given-names>EM</given-names></name><name><surname>Tan</surname><given-names>AJ</given-names></name><name><surname>Tennant</surname><given-names>RC</given-names></name><name><surname>Maus</surname><given-names>JG</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>1974</fpage><lpage>1979</lpage><pub-id pub-id-type="pmid">16236844</pub-id></element-citation></ref><ref id="b22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Chapman</surname><given-names>KR</given-names></name><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>Mahler</surname><given-names>DA</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name></person-group><article-title>Minimal clinically important differences in pharmacological trials</article-title><source>Am J Respir Crit Care Med</source><year>2014</year><volume>189</volume><fpage>250</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">24383418</pub-id></element-citation></ref><ref id="b23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>FB</given-names></name><name><surname>Kaiser</surname><given-names>DL</given-names></name><name><surname>Kowal</surname><given-names>MB</given-names></name><name><surname>Suratt</surname><given-names>PM</given-names></name></person-group><article-title>Prolonged effect of inhaled glycopyrrolate in asthma</article-title><source>Chest</source><year>1987</year><volume>91</volume><fpage>49</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">3792086</pub-id></element-citation></ref><ref id="b24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzelepis</surname><given-names>G</given-names></name><name><surname>Komanapolli</surname><given-names>S</given-names></name><name><surname>Tyler</surname><given-names>D</given-names></name><name><surname>Vega</surname><given-names>D</given-names></name><name><surname>Fulambarker</surname><given-names>A</given-names></name></person-group><article-title>Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>1996</year><volume>9</volume><fpage>100</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">8834341</pub-id></element-citation></ref><ref id="b25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buhl</surname><given-names>R</given-names></name><name><surname>Banerji</surname><given-names>D</given-names></name></person-group><article-title>Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2012</year><volume>7</volume><fpage>729</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">23118536</pub-id></element-citation></ref><ref id="b26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerwin</surname><given-names>E</given-names></name><name><surname>H&#x000e9;bert</surname><given-names>J</given-names></name><name><surname>Gallagher</surname><given-names>N</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Overend</surname><given-names>T</given-names></name><name><surname>Alagappan</surname><given-names>VK</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Banerji</surname><given-names>D</given-names></name></person-group><article-title>Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study</article-title><source>Eur Respir J</source><year>2012</year><volume>40</volume><fpage>1106</fpage><lpage>1114</lpage><pub-id pub-id-type="pmid">23060624</pub-id></element-citation></ref><ref id="b27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Di Scala</surname><given-names>L</given-names></name><name><surname>Drollmann</surname><given-names>A</given-names></name></person-group><article-title>Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2012</year><volume>7</volume><fpage>503</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">22973092</pub-id></element-citation></ref><ref id="b28"><element-citation publication-type="other"><collab>Register ECT</collab><year>2011</year><comment>EudraCT 2011-003588-31. Available at <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003588-31/GB">https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003588-31/GB</ext-link> (last accessed 9 October 2014)</comment></element-citation></ref><ref id="b29"><element-citation publication-type="other"><collab>Register ECT</collab><year>2012</year><comment>EudraCT 2011-004759-37. Available at <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004759-37/GB">https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004759-37/GB</ext-link> (last accessed 9 October 2014)</comment></element-citation></ref><ref id="b30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedzicha</surname><given-names>JA</given-names></name><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>Ficker</surname><given-names>JH</given-names></name><name><surname>Niewoehner</surname><given-names>DE</given-names></name><name><surname>Sandstr&#x000f6;m</surname><given-names>T</given-names></name><name><surname>Taylor</surname><given-names>AF</given-names></name><name><surname>D'Andrea</surname><given-names>P</given-names></name><name><surname>Arrasate</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Banerji</surname><given-names>D</given-names></name></person-group><article-title>Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study</article-title><source>Lancet Respir Med</source><year>2013</year><volume>1</volume><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">24429126</pub-id></element-citation></ref><ref id="b31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sestini</surname><given-names>P</given-names></name><name><surname>Cappiello</surname><given-names>V</given-names></name><name><surname>Aliani</surname><given-names>M</given-names></name><name><surname>Martucci</surname><given-names>P</given-names></name><name><surname>Sena</surname><given-names>A</given-names></name><name><surname>Vaghi</surname><given-names>A</given-names></name><name><surname>Canessa</surname><given-names>PA</given-names></name><name><surname>Neri</surname><given-names>M</given-names></name><name><surname>Melani</surname><given-names>AS</given-names></name></person-group><collab>Group AIPOE</collab><article-title>Prescription bias and factors associated with improper use of inhalers</article-title><source>J Aerosol Med</source><year>2006</year><volume>19</volume><fpage>127</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">16796537</pub-id></element-citation></ref><ref id="b32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rau</surname><given-names>JL</given-names></name></person-group><article-title>Practical problems with aerosol therapy in COPD</article-title><source>Respir Care</source><year>2006</year><volume>51</volume><fpage>158</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">16441960</pub-id></element-citation></ref><ref id="b33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanania</surname><given-names>NA</given-names></name><name><surname>Donohue</surname><given-names>JF</given-names></name></person-group><article-title>Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators</article-title><source>Proc Am Thorac Soc</source><year>2007</year><volume>4</volume><fpage>526</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">17878465</pub-id></element-citation></ref><ref id="b34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barta</surname><given-names>SK</given-names></name><name><surname>Crawford</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>CM</given-names></name></person-group><article-title>Survey of patients' views of domiciliary nebuliser treatment for chronic lung disease</article-title><source>Respir Med</source><year>2002</year><volume>96</volume><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">12117035</pub-id></element-citation></ref><ref id="b35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>R</given-names></name><name><surname>Greefhorst</surname><given-names>LA</given-names></name><name><surname>Nowak</surname><given-names>D</given-names></name><name><surname>Nonikov</surname><given-names>V</given-names></name><name><surname>Byrne</surname><given-names>AM</given-names></name><name><surname>Thomson</surname><given-names>MH</given-names></name><name><surname>Till</surname><given-names>D</given-names></name><name><surname>Della Cioppa</surname><given-names>G</given-names></name></person-group><collab>Group FiCOPDIS</collab><article-title>Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>778</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">11549532</pub-id></element-citation></ref><ref id="b36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moulton</surname><given-names>BC</given-names></name><name><surname>Fryer</surname><given-names>AD</given-names></name></person-group><article-title>Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD</article-title><source>Br J Pharmacol</source><year>2011</year><volume>163</volume><fpage>44</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">21198547</pub-id></element-citation></ref><ref id="b37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>N</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name><name><surname>Izumo</surname><given-names>T</given-names></name><name><surname>Tamaoki</surname><given-names>J</given-names></name><name><surname>Nagai</surname><given-names>A</given-names></name></person-group><article-title>Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice</article-title><source>Eur Respir J</source><year>2010</year><volume>35</volume><fpage>1164</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">19897560</pub-id></element-citation></ref><ref id="b38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>KC</given-names></name><name><surname>Billington</surname><given-names>CK</given-names></name><name><surname>Gandhi</surname><given-names>U</given-names></name><name><surname>Panettieri</surname><given-names>RA</given-names></name><name><surname>Penn</surname><given-names>RB</given-names></name></person-group><article-title>Cooperative mitogenic signaling by G protein-coupled receptors and growth factors is dependent on G(q/11)</article-title><source>FASEB J</source><year>2006</year><volume>20</volume><fpage>1558</fpage><lpage>1560</lpage><pub-id pub-id-type="pmid">16723377</pub-id></element-citation></ref><ref id="b39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosens</surname><given-names>R</given-names></name><name><surname>Dueck</surname><given-names>G</given-names></name><name><surname>Rector</surname><given-names>E</given-names></name><name><surname>Nunes</surname><given-names>RO</given-names></name><name><surname>Gerthoffer</surname><given-names>WT</given-names></name><name><surname>Unruh</surname><given-names>H</given-names></name><name><surname>Zaagsma</surname><given-names>J</given-names></name><name><surname>Meurs</surname><given-names>H</given-names></name><name><surname>Halayko</surname><given-names>AJ</given-names></name></person-group><article-title>Cooperative regulation of GSK-3 by muscarinic and PDGF receptors is associated with airway myocyte proliferation</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2007</year><volume>293</volume><fpage>L1348</fpage><lpage>1358</lpage><pub-id pub-id-type="pmid">17873004</pub-id></element-citation></ref><ref id="b40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogg</surname><given-names>JC</given-names></name><name><surname>Chu</surname><given-names>F</given-names></name><name><surname>Utokaparch</surname><given-names>S</given-names></name><name><surname>Woods</surname><given-names>R</given-names></name><name><surname>Elliott</surname><given-names>WM</given-names></name><name><surname>Buzatu</surname><given-names>L</given-names></name><name><surname>Cherniack</surname><given-names>RM</given-names></name><name><surname>Rogers</surname><given-names>RM</given-names></name><name><surname>Sciurba</surname><given-names>FC</given-names></name><name><surname>Coxson</surname><given-names>HO</given-names></name><name><surname>Par&#x000e9;</surname><given-names>PD</given-names></name></person-group><article-title>The nature of small-airway obstruction in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>2645</fpage><lpage>2653</lpage><pub-id pub-id-type="pmid">15215480</pub-id></element-citation></ref><ref id="b41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kistemaker</surname><given-names>LE</given-names></name><name><surname>Oenema</surname><given-names>TA</given-names></name><name><surname>Meurs</surname><given-names>H</given-names></name><name><surname>Gosens</surname><given-names>R</given-names></name></person-group><article-title>Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD</article-title><source>Life Sci</source><year>2012</year><volume>91</volume><fpage>1126</fpage><lpage>1133</lpage><pub-id pub-id-type="pmid">22406302</pub-id></element-citation></ref><ref id="b42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosens</surname><given-names>R</given-names></name><name><surname>Bos</surname><given-names>IS</given-names></name><name><surname>Zaagsma</surname><given-names>J</given-names></name><name><surname>Meurs</surname><given-names>H</given-names></name></person-group><article-title>Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling</article-title><source>Am J Respir Crit Care Med</source><year>2005</year><volume>171</volume><fpage>1096</fpage><lpage>1102</lpage><pub-id pub-id-type="pmid">15695490</pub-id></element-citation></ref><ref id="b43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grainge</surname><given-names>CL</given-names></name><name><surname>Lau</surname><given-names>LC</given-names></name><name><surname>Ward</surname><given-names>JA</given-names></name><name><surname>Dulay</surname><given-names>V</given-names></name><name><surname>Lahiff</surname><given-names>G</given-names></name><name><surname>Wilson</surname><given-names>S</given-names></name><name><surname>Holgate</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>DE</given-names></name><name><surname>Howarth</surname><given-names>PH</given-names></name></person-group><article-title>Effect of bronchoconstriction on airway remodeling in asthma</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><fpage>2006</fpage><lpage>2015</lpage><pub-id pub-id-type="pmid">21612469</pub-id></element-citation></ref></ref-list></back></article>